Table 6.
Subgroup analysis in the participants whose HOMA-IR levels were more than 1.6 at week 0 test.
| Variable | Group | Week 0 | Week 4 | Week 8 | Week 12 | 12-Week Change |
|---|---|---|---|---|---|---|
| FBG (mg/dL) | Placebo | 107.1 ± 8.2 | 103.9 ± 8.1 | 109.3 ± 10.9 | 105.5 ± 10.2 | −1.6 ± 10.5 |
| OLL2712 | 104.7 ± 8.7 | 102.6 ± 8.4 | 103.7 ± 11.7 | 100.0 ± 11.4 | −4.7 ± 10.6 | |
| HbA1c (%) | Placebo | 5.94 ± 0.18 | 5.88 ± 0.20 | 6.01 ± 0.21 | 5.90 ± 0.26 | −0.03 ± 0.17 |
| OLL2712 | 5.94 ± 0.23 | 5.92 ± 0.23 | 5.99 ± 0.24 | 5.89 ± 0.29 | −0.05 ± 0.17 | |
| GA (%) | Placebo | 14.6 ± 1.5 | 14.6 ± 1.5 | 14.5 ± 1.4 | 14.5 ± 1.5 | −0.1 ± 0.5 |
| OLL2712 | 14.4 ± 1.1 | 14.3 ± 1.0 | 14.1 ± 1.0 ** | 14.2 ± 1.1 * | −0.3 ± 0.5 | |
| Insulin (μU/mL) | Placebo | 8.61 ± 2.88 | 9.13 ± 2.66 | 9.38 ± 3.30 | 10.88 ± 5.03 | 2.27 ± 5.30 |
| OLL2712 | 10.53 ± 6.93 | 8.40 ± 3.29 | 9.09 ± 3.15 | 8.68 ± 4.02 | −1.85 ± 7.81 | |
| HOMA-IR | Placebo | 2.23 ± 0.89 | 2.34 ± 0.70 | 2.57 ± 1.05 | 2.89 ± 1.51 | 0.60 ± 1.55 |
| OLL2712 | 2.74 ± 1.97 | 2.12 ± 0.84 | 2.32 ± 0.76 | 2.15 ± 0.97 | −0.59 ± 2.22 |
Abbreviations: FBG, fasting blood glucose; GA, glycoalbumin; HbA1c, whole blood hemoglobin A1c; HOMA-IR, homeostasis model assessment of insulin resistance. Data are presented as mean ± SD (n = 21 in the placebo group and n = 17 in the OLL2712 group). Significant differences compared to measurements at week 0 (baseline) were determined by the Dunnett’s test or the Wilcoxon signed-rank test (* p < 0.05, ** p < 0.01). Significant differences compared to the placebo group were determined by the unpaired t-test or the Mann–Whitney U test, and there were no significant differences.